PRAX Valuation

Praxis Precision Medicines Inc

Add to Watchlist

Advanced Chart

45.540

-0.45(-0.978%)1D

Overview
Forecast
Valuation
Earnings

PRAX Relative Valuation

PRAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRAX is overvalued; if below, it's undervalued.

Historical Valuation

Praxis Precision Medicines Inc (PRAX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 2629.44 is considered Overvalued compared with the five-year average of -4.77. The fair price of Praxis Precision Medicines Inc (PRAX) is between 21.68 to 41.13 according to relative valuation methord. Compared to the current price of 45.54 USD , Praxis Precision Medicines Inc is Overvalued By 10.73%.

Relative Value

Fair Zone

21.68-41.13

Current Price：45.54

10.73%

Overvalued

-3.37

Trailing

Forward

-1.90

EV/EBITDA

Praxis Precision Medicines Inc. (PRAX) has a current EV/EBITDA of -1.90. The 5-year average EV/EBITDA is -3.08. The thresholds are as follows: Strongly Undervalued below -11.27, Undervalued between -11.27 and -7.18, Fairly Valued between 1.01 and -7.18, Overvalued between 1.01 and 5.11, and Strongly Overvalued above 5.11. The current Forward EV/EBITDA of -1.90 falls within the Historic Trend Line -Fairly Valued range.

-1.67

EV/EBIT

Praxis Precision Medicines Inc. (PRAX) has a current EV/EBIT of -1.67. The 5-year average EV/EBIT is -3.13. The thresholds are as follows: Strongly Undervalued below -12.20, Undervalued between -12.20 and -7.66, Fairly Valued between 1.41 and -7.66, Overvalued between 1.41 and 5.94, and Strongly Overvalued above 5.94. The current Forward EV/EBIT of -1.67 falls within the Historic Trend Line -Fairly Valued range.

2629.44

Praxis Precision Medicines Inc. (PRAX) has a current PS of 2629.44. The 5-year average PS is 341.76. The thresholds are as follows: Strongly Undervalued below -879.51, Undervalued between -879.51 and -268.87, Fairly Valued between 952.39 and -268.87, Overvalued between 952.39 and 1563.03, and Strongly Overvalued above 1563.03. The current Forward PS of 2629.44 falls within the Strongly Overvalued range.

-3.86

P/OCF

Praxis Precision Medicines Inc. (PRAX) has a current P/OCF of -3.86. The 5-year average P/OCF is -5.53. The thresholds are as follows: Strongly Undervalued below -16.65, Undervalued between -16.65 and -11.09, Fairly Valued between 0.03 and -11.09, Overvalued between 0.03 and 5.60, and Strongly Overvalued above 5.60. The current Forward P/OCF of -3.86 falls within the Historic Trend Line -Fairly Valued range.

-3.02

P/FCF

Praxis Precision Medicines Inc. (PRAX) has a current P/FCF of -3.02. The 5-year average P/FCF is -5.18. The thresholds are as follows: Strongly Undervalued below -15.22, Undervalued between -15.22 and -10.20, Fairly Valued between -0.16 and -10.20, Overvalued between -0.16 and 4.86, and Strongly Overvalued above 4.86. The current Forward P/FCF of -3.02 falls within the Historic Trend Line -Fairly Valued range.

Praxis Precision Medicines Inc (PRAX) has a current Price-to-Book (P/B) ratio of 2.37. Compared to its 3-year average P/B ratio of 2.29 , the current P/B ratio is approximately 3.71% higher. Relative to its 5-year average P/B ratio of 2.42, the current P/B ratio is about -2.03% higher. Praxis Precision Medicines Inc (PRAX) has a Forward Free Cash Flow (FCF) yield of approximately -19.77%. Compared to its 3-year average FCF yield of -81.99%, the current FCF yield is approximately -75.88% lower. Relative to its 5-year average FCF yield of -60.86% , the current FCF yield is about -67.51% lower.

2.37

P/B

Median3y

2.29

Median5y

2.42

-19.77

FCF Yield

Median3y

-81.99

Median5y

-60.86

Competitors Valuation Multiple

The average P/S ratio for PRAX's competitors is 3255.32, providing a benchmark for relative valuation. Praxis Precision Medicines Inc Corp (PRAX) exhibits a P/S ratio of 2629.44, which is -19.23% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PRAX.O

Praxis Precision Medicines Inc

Spyre Therapeutics Inc

10099.04

996.01M

ATAI.O

ATAI Life Sciences NV

Oric Pharmaceuticals Inc

Loss

993.57M

Performance Decomposition

Market capitalization of PRAX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of PRAX in the past 1 year is driven by Unknown.